TGV
RAPP

TRV GP V’s Rapport Therapeutics RAPP Stock Holding History

TRV GP V’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223M Hold
7,135,233
– – 55.68% 1
2025
Q4 		$216M Hold
7,135,233
– – 50.44% 1
2025
Q3 		$212M Hold
7,135,233
– – 59.95% 1
2025
Q2 		$81.1M Hold
7,135,233
– – 48.98% 1
2025
Q1 		$71.6M Hold
7,135,233
– – 57.21% 1
2024
Q4 		$127M Buy
+7,135,233
New +$158M 43.06% 2

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TRV GP V's RAPP Position: Q1 2026 in Review

TRV GP V held its Rapport Therapeutics (RAPP) position steady in Q1 2026 at 7,135,233 shares worth $223M. The position accounts for 55.68% of the portfolio, ranked #1.

TRV GP V first reported a position in RAPP in Q4 2024 and has held it in 6 quarters since. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • TRV GP V held 7,135,233 shares of Rapport Therapeutics worth $223M as of Q1 2026.
  • TRV GP V left its Rapport Therapeutics share count unchanged in Q1 2026.
  • Rapport Therapeutics made up 55.68% of TRV GP V's portfolio in Q1 2026, its #1 holding.
  • TRV GP V first reported a position in Rapport Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on TRV GP V's 13F filing for Q1 2026, filed 7 May 2026.